Does Rallies show 13F holders for HAE?

Yes. Rallies tracks hedge fund and 13F ownership data for HAE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is HAE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HAE. It does not provide personalized investment advice.

HAE (Haemonetics Corporation) Stock Analysis - Hedge Fund Holdings

Haemonetics Corporation (HAE) is a publicly traded Healthcare sector company. As of May 21, 2026, HAE trades at $59.56 with a market cap of $2.66B and a P/E ratio of 16.25. HAE moved +4.51% today. Year to date, HAE is -27.46%; over the trailing twelve months it is -13.57%. Its 52-week range spans $47.32 to $94.99. Analyst consensus is buy with an average price target of $72.67. Rallies surfaces HAE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns HAE stock?

Hedge funds tracked by Rallies that own HAE include Bridgewater Associates, Pinebridge Investments, Mangrove Partners, Panagora Asset, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Haemonetics Corporation.

HAE Key Metrics

Key financial metrics for HAE
Metric	Value
Price	$59.56
Market Cap	$2.66B
P/E Ratio	16.25
EPS	$3.64
Dividend Yield	0.00%
52-Week High	$94.99
52-Week Low	$47.32
Volume	0
Avg Volume	0
Revenue (TTM)	$1.32B
Net Income	$175.44M
Gross Margin	59.35%

Top Hedge Funds Holding HAE

Bridgewater Associates holds 48.38K shares of HAE, changed -18.15% as of Mar 31, 2026.
Pinebridge Investments holds 22.48K shares of HAE, changed +42.69% as of Dec 31, 2024.
Mangrove Partners holds 21.37K shares of HAE, changed +606.25% as of Mar 31, 2026.
Panagora Asset holds 21.36K shares of HAE, changed -36.81% as of Mar 31, 2026.
Centerbook Partners holds 6.65K shares of HAE, changed +0.00% as of Sep 30, 2025.

Latest HAE News

Haemonetics Q4 EPS of $1.29 Beats Estimates, Up 4% Year-over-Year — May 7, 2026
Haemonetics Forecasts 1.4% Price Hike and €12.5m FX Hit in 2026 — Mar 31, 2026
Haemonetics Gains FDA Clearance for NexSys PCS, Persona PLUS Boosts Yield by Mid-Single Digits — Feb 23, 2026
Haemonetics' Q3 Revenue Hits $339M as Fund Highlights Earnings Beat, Shares Slide 20% — Feb 16, 2026
Haemonetics Hold Rating Persists Despite 6.8% Q3 Surprise, 8.1% Growth Forecast — Feb 6, 2026

Recent HAE Insider Trades

KROLL MARK W bought 1.40K (~$98.78K) on Nov 10, 2025.
Strong Stewart W sold 4.31K (~$393.04K) on Jul 26, 2024.
Lingamneni Anila sold 79 (~$7.11K) on Jul 12, 2024.

HAE Analyst Consensus

7 analysts cover HAE: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $72.67.

Common questions about HAE

Who owns HAE stock?: Hedge funds tracked by Rallies that own HAE include Bridgewater Associates, Pinebridge Investments, Mangrove Partners, Panagora Asset, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Haemonetics Corporation.
Does Rallies show 13F holders for HAE?: Yes. Rallies tracks hedge fund and 13F ownership data for HAE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HAE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HAE. It does not provide personalized investment advice.